ArticleScience advances2021
The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 57 citations in OpenAlex.
- Article
- Carbene-Ketene Formal [3 + 2] Cycloaddition Enabled by Visible-Light-Induced Dual Photolysis of Diazo Compounds.JACS Au · 2026Article
- Glutaredoxin 1 promotes intestinal epithelial cell copper toxicity in inflammatory bowel disease.Redox biology · 2026Article
- Ammonia Detoxification Inhibits Liver Metastasis by Reshaping Hepatic Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Pirfenidone Sensitizes Hepatic Stellate Cells to Ferroptosis by Reprogramming Glutamine and Serine Metabolism for GSH Depletion.Antioxidants (Basel, Switzerland) · 2026Article
- RYK is a GPNMB receptor that drives MASH.Nature · 2026Article
- Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- Targeting macrophages in liver fibrosis.Frontiers in immunology · 2026Review
- Emerging nanomedicine for liver diseases treatment.Journal of nanobiotechnology · 2025Review
- A loss-of-function human ADAR variant activates innate immune response and promotes bowel inflammation.Nature communications · 2025Article
- Exploring Cirrhosis: Insights into Advances in Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Amelioration of Liver Fibrosis via In Situ Hepatic Stellate Cell Conversion Through Co-Inhibition of TGF-β and GSK-3 Signalling.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- The desulfinylation enzyme sulfiredoxin-1 attenuates HSC activation and liver fibrosis by modulating the PTPN12-NLRP3 axis.Hepatology (Baltimore, Md.) · 2025Article
- Article
- Exploring the potential of herbal drugs for treating liver fibrosis: a computational screening approach.Asian biomedicine : research, reviews and news · 2025Article
- Article
- Ciliary and Non-Ciliary Roles of IFT88 in Development and Diseases.International journal of molecular sciences · 2025Review
- H3K9me3 demethylation by JMJD2B is regulated by pirfenidone resulting in improved NASH.Scientific reports · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 2 countries.
Yue XiCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0003-1265-6624
Yanping LiDepartment of Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.ORCID 0000-0003-1811-0083
Pengfei XuCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0001-6854-6040
Sihan LiCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Zhengsheng LiuDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
Hung-Chun TungCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0002-9854-6831
Xinran CaiCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0003-4562-3538
Jingyuan WangCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0003-1180-5050
Haozhe HuangCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Menglin WangDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0002-5348-5983
Meishu XuCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Songrong RenCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0001-6797-6188
Song LiCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0003-1658-949X
Min ZhangCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0001-8327-6405
Yong J LeeDepartment of Surgery, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0001-5914-8489
Leaf HuangDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0002-9421-8283
Da YangCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0002-8336-9457
Jinhan HeDepartment of Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zhiying HuangSchool of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.ORCID 0000-0002-9203-9302
Wen XieCenter for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0003-3967-155X
University of Pittsburgh · USUniversity of North Carolina at Chapel Hill · USSichuan University · CNSun Yat-sen University · CN
Funding
Xenobiotic Receptors in Mediating the Environmental Effects on Human Disease and MorbidityR35ES030429 · NIEHS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Wen Xie · 2019 to 2026
$6.9MNIEHS NIH HHS R35 ES030429
Abstract
Activation of the hepatic stellate cells (HSCs) is a key pathogenic event in liver fibrosis. Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.